Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19214733 | 0.78 | ALDH1A1 (0.52) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL18733004 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL13616897 | 0.74 | ALDH1A1 (0.55) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL16447617 | 0.72 | ALDH1A1 (0.64) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL13299192 | 0.72 | ALDH1A1 (0.53) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL6114653 | 0.71 | GLS (0.67) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL19214738 | 0.71 | GLS (0.47) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL2020938 | 0.71 | — | — | |
| SCHEMBL3506904 | 0.71 | ALDH1A1 (0.52) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL10277522 | 0.70 | LMNA (0.44) | ALDH1A1KDM4EGLAGLSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993775-B2 | Chromium and nickel catalysts for oligomerization reactions and process for obtaining alpha-olefins using said catalysts | Petroleo Brasileiro S.A.—Petrobras (BR) | 2015-03-31 | — | — | US | disclosed |
| US-20120178939-A1 | Chromium and nickel catalysts for oligomerization recations and process for obtaining alpha-olefins using said catalysts | UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL - UFRGS (BR) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178939-A1 | Chromium and nickel catalysts for oligomerization recations and process for obtaining alpha-olefins using said catalysts | PCNA, ORC3, AOC3 | ALDH1A1 3506/4885KDM4E 4417/4885GLA 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.